SVCM
ANAB icon

Saturn V Capital Management’s AnaptysBio ANAB Stock Holding History

Saturn V Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-249,609
Closed -$6.26M – 26
2024
Q2 		$6.26M Sell
249,609
-336,422
-57% -$7.83M 2.36% 17
2024
Q1 		$13.2M Sell
586,031
-78,245
-12% -$1.85M 5.29% 8
2023
Q4 		$14.2M Buy
664,276
+87,175
+15% +$1.5M 5.45% 8
2023
Q3 		$10.4M Buy
+577,101
New +$11M 4.34% 13

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Saturn V Capital Management's ANAB Position: Q3 2024 in Review

Saturn V Capital Management sold out of AnaptysBio (ANAB) in Q3 2024, closing a stake of 249,609 shares — an estimated $6.26M sold.

Saturn V Capital Management first reported a position in ANAB in Q3 2023 and held it in 4 quarters. The position peaked at $14.2M in Q4 2023. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2024.

  • Saturn V Capital Management reported no remaining AnaptysBio position as of Q3 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 249,609 AnaptysBio shares in Q3 2024, an estimated $6.26M.
  • Saturn V Capital Management first reported a position in AnaptysBio in Q3 2023 and held it in 4 quarters.
  • Saturn V Capital Management's AnaptysBio position peaked at $14.2M in Q4 2023.
  • 160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2024.

Based on Saturn V Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.